MACSiMiSE-BRAIN
Metformin
Progressive MS · phase 2 · 120 participants
Main results due Feb 2027
Progression
Assembled by software from public sources.
Metformin
Progressive MS · phase 2 · 120 participants
Main results due Feb 2027
Progression
Stopping or reducing treatment
Progressive MS · phase 3 · 250 participants
Main results due Jul 2027
Progression
Cell therapies and tolerisation
Progressive MS · phase 2 · 45 participants
Main results due Oct 2027
Progression
| Area | Due | Trial | Tests | Type of MS | Phase | Participants |
|---|---|---|---|---|---|---|
| 2027 | ||||||
| Progression | Dec 2027 | ChariotMS | Cladribine | Progressive MS | phase 3 | 204 |
| 2028 | ||||||
| Progression | Mar 2028 | FREVIVA | Frexalimab | Relapsing and progressive MS | phase 3 | 943 |
| 2030 | ||||||
| Progression | Jun 2030 | Orelabrutinib, phase 3 | Orelabrutinib | Relapsing and progressive MS | phase 3 | 990 |
| Progression | Jun 2030 | Orelabrutinib, phase 3 | Orelabrutinib | Progressive MS | phase 3 | 705 |
| Progression | Dec 2030 | REMASTER | Remibrutinib | Progressive MS | phase 3 | 1,275 |